Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, un